# Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

> **NCT02228096** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 75 (actual)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Relapsed B-cell Acute Lymphoblastic Leukemia
- Refractory B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CTL019 T-cells

## Key facts

- **NCT ID:** NCT02228096
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-14
- **Primary completion:** 2018-05-29
- **Final completion:** 2019-05-24
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228096, "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02228096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*